menu
    • menu
    [{"orgOrder":0,"company":"Cerus Corporation","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Funding","leadProduct":"Intercept treated Red Blood Cells","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Cerus Corporation","amount2":0.20999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.20999999999999999,"dosageForm":"","sponsorNew":"Cerus Corporation \/ BARDA","highestDevelopmentStatusID":"10","companyTruncated":"Cerus Corporation \/ BARDA"},{"orgOrder":0,"company":"Cerus Corporation","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Large molecule","year":"2022","type":"Funding","leadProduct":"Pathogen Reduced Lyophilized Cryoprecipitate","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"Cerus Corporation","amount2":0.01,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","amount2New":0.01,"dosageForm":"","sponsorNew":"Cerus Corporation \/ U.S. Department of Defense","highestDevelopmentStatusID":"1","companyTruncated":"Cerus Corporation \/ U.S. Department of Defense"}]

    Find Clinical Drug Pipeline Developments & Deals by Cerus Corporation

    Menu

    Cerus Corporation

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Cerus Corporation

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed

                            Cerus Corporation

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pathogen Reduced Lyophilized Cryoprecipitate

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Undisclosed

                            Sponsor : U.S. Department of Defense

                            Deal Size : $9.1 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Cerus Corporation Announces Award of U.S. Department of Defense Funding for Development of Pathogen Reduced, L...

                            Details : Cerus’ LyoCryo, a pathogen reduced, lyophilized cryoprecipitate, is being designed for shelf stability, rapid availability, and portability, enabling administration to patients in remote environments with the aim of increasing survival from traumatic i...

                            Brand Name : LyoCryo

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            November 02, 2022

                            Lead Product(s) : Pathogen Reduced Lyophilized Cryoprecipitate

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Undisclosed

                            Sponsor : U.S. Department of Defense

                            Deal Size : $9.1 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Cerus Corporation

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed

                            Cerus Corporation

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Intercept treated Red Blood Cells

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : BARDA

                            Deal Size : $214.0 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Cerus Expands BARDA Funding by Additional $14M

                            Details : Funding boosts further evaluation of the INTERCEPT Blood System's effectiveness in inactivating SARS-CoV-2 in all three blood components beyond what has already been identified.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            April 20, 2020

                            Lead Product(s) : Intercept treated Red Blood Cells

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : BARDA

                            Deal Size : $214.0 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth